Progress in the Treatment of Amyotrophic Lateral Sclerosis (ALS)

A panel of key opinion leaders in neurology provides an overview of the prevalence of amyotrophic lateral sclerosis (ALS) and discusses potential causes and risk factors.

Expert neurologists discuss the variability of signs and symptoms as well as other factors to consider when diagnosing patients with amyotrophic lateral sclerosis (ALS).

Panelists provide insight into what primary care physicians should consider when differentiating amyotrophic lateral sclerosis (ALS) from conditions with similar presentations. 

Key opinion leaders ALS care comment on best practices when communicating with patients about the unpredictability of disease progression and prognosis.

A panel of experts considers the usefulness of diagnostic criteria and disease staging systems for patients with amyotrophic lateral sclerosis (ALS) as entry criteria for clinical trials.

Experts in neurology give insight into recent advancements in genetic testing for amyotrophic lateral sclerosis (ALS) and discuss what factors to consider when offering it to patients.

A panel of key opinion leaders provides insight into how COVID-19 has continued to impact the diagnosis and management of patients with amyotrophic lateral sclerosis (ALS). 

Expert neurologists discuss the importance of a multidisciplinary approach to the management of symptoms for palliative care in amyotrophic lateral sclerosis (ALS).

Panelists share approaches for building a dialogue on life sustaining care such as invasive ventilation and discuss the importance of social and cultural factors for patients and families.

Key opinion leaders consider the importance of respiratory care in ALS by discussing immunization against respiratory illness as well as the use of non-invasive ventilation.

Expert neurologists discuss clinical trial design and FDA approvals for current approaches to pharmacologic management of amyotrophic lateral sclerosis (ALS) and share personal experiences.

A panel of experts provides insights into recent improvements in clinical trial design in amyotrophic lateral sclerosis (ALS) and discusses implications of recent clinical trial results.

Key opinion leaders review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis (ALS).